



vaccines



an Open Access Journal by MDPI

Advances in Cancer Immunotherapy and Vaccines Research: 2nd Edition

Guest Editor:

Dr. Takumi Kumai

Department of Otolaryngology
Head and Neck Surgery,
Asahikawa Medical University,
Midorigaoka East 2-1-1-1,
Asahikawa, Hokkaido 0788510,
Japan

Deadline for manuscript
submissions:

20 March 2025

Message from the Guest Editor

Immunotherapy is now a standard therapy in addition to surgery, chemotherapy, and radiotherapy for treating cancer. Immune checkpoint blockades are a form of immunotherapy that have acceptable results in many types of tumors. However, it only works for around 20% of patients, as it depends on the immune cells already present in the tumor microenvironment. If these cells are lacking or exhausted, the treatment is not effective. Tumor vaccines can help by increasing the number of antitumor immune cells, including CD8 T cells and CD4 T cells. Peptide epitopes from tumor-associated antigens (TAAs) can be used to develop a tumor vaccine. In the past, vaccines using tumor-derived peptides and inadequate adjuvants (such as incomplete Freund's adjuvant) failed to achieve clinical antitumor effects. However, with improvements in our understanding of the immune system, we can now use peptides, costimulatory molecules, and cytokines in combination with adequate adjuvants to expand T cells and impede the immune-suppressive environment. This Special Issue will gather the latest advances in the field of tumor immunology to optimize tumor vaccines.



mdpi.com/si/197302

Special Issue



an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious
Diseases, College of Veterinary
Medicine, University of Georgia,
Athens, GA 30602-7387, USA

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Author Benefits

Open Access: free for readers, with **article processing charges (APC)** paid by authors or their institutions.

High Visibility: indexed within **Scopus**, **SCIE (Web of Science)**, **PubMed**, **PMC**, **Embase**, **CAPus / SciFinder**, and **other databases**.

Journal Rank: JCR - Q1 (*Immunology*) / CiteScore - Q1 (*Pharmacology (medical)*)

Contact Us

Vaccines Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/vaccines
vaccines@mdpi.com